Table 2. Morphoproteomic scoring of protein expression in biopsied tissue from patients with metastatic renal cell carcinoma progressing on rapalog therapy.
| ID | Classification | Rapalog | Months to biopsy | Biopsy site | Scores | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| p-ERK | p-Akt | p-mTOR | p-STAT3 | IGF-1R | EZH2 | |||||
| 1 | Clear cell | Everolimus (+metformin) | 26.5 | Lung | Up to 3+ | Up to 2+ | Up to 3+ | Up to 3+ (~100%) | ± – 3+ (> 50%) | Up to > 50% |
| 2 | Clear cell | Everolimus (+metformin) | 6.23 | Bone | Up to 3+ | Up to 2+ | Up to 3+ | 3 (~50%) | 1–2+ ~100% | 10–20% |
| 3 | Conventional | Everolimus | 0.30 | Lung | Up to 2+ | Up to 2+ | Up to 2+ | Up to 2+ (~30%) | 2–3+ (> 50%) | Up to > 50% |
| 4 | Papillary | Everolimus | 6.07 | Lymph Node | Up to 3+ | Up to 3 | Up to 3+ | Up to 3+ (~30%) | 2–3+ (> 50%) | > 50% |
| 5 | Rare atypical | Everolimus | 5.80 | Lung | Up to 3+ | Up to 3 | Up to 3+ | Up to 3+ (~100%) | 2+ (~100%) | ~20% |
| 6 | Clear cell | Everolimus (+metformin) | 35.07 | Bone | Up to 3+ | Up to 3+ | Up to 2+ | Up to 3+ (~100%) | 0–2+ (> 50%) | ~20% |
| 7 | Sarcomatoid | Temsirolimus | 2.73 | Soft tissue | Up to 3+ | Up to 3+ | Up to 3+ | 3+ (> 50%) | 1–3+ | >50% |
| 8 | Clear cell | Everolimus, Temsirolimus | 33.3 | Soft tissue | Up to 3+ | Up to 2+ | Up to 2+ | Up to 3+ (~50%) | 0–1+ (< 50%) | < 10% |
| 9 | Clear cell | Temsirolimus | 7.9 | Lung | Up to 3+ | 1–2+ | 1–3+ | 1–3+ (~100%) | 1–3+ (> 50%) | Up to > 50% |